HomeCompareCFRUY vs ABBV

CFRUY vs ABBV: Dividend Comparison 2026

CFRUY yields 1.01% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $16.1K in total portfolio value
10 years
CFRUY
CFRUY
● Live price
1.01%
Share price
$17.29
Annual div
$0.18
5Y div CAGR
60.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$86.2K
Annual income
$31,678.26
Full CFRUY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CFRUY vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCFRUYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CFRUY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CFRUY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CFRUY
Annual income on $10K today (after 15% tax)
$86.13/yr
After 10yr DRIP, annual income (after tax)
$26,926.52/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CFRUY beats the other by $5,870.52/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CFRUY + ABBV for your $10,000?

CFRUY: 50%ABBV: 50%
100% ABBV50/50100% CFRUY
Portfolio after 10yr
$94.3K
Annual income
$28,225.01/yr
Blended yield
29.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CFRUY
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
5.5
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CFRUY buys
0
ABBV buys
0
No recent congressional trades found for CFRUY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCFRUYABBV
Forward yield1.01%3.06%
Annual dividend / share$0.18$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR60.4%40.6%
Portfolio after 10y$86.2K$102.3K
Annual income after 10y$31,678.26$24,771.77
Total dividends collected$61.6K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: CFRUY vs ABBV ($10,000, DRIP)

YearCFRUY PortfolioCFRUY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,863$162.52$11,550$430.00$687.00ABBV
2$11,888$264.65$13,472$627.96$1.6KABBV
3$13,154$434.16$15,906$926.08$2.8KABBV
4$14,795$720.17$19,071$1,382.55$4.3KABBV
5$17,045$1,214.25$23,302$2,095.81$6.3KABBV
6$20,335$2,097.06$29,150$3,237.93$8.8KABBV
7$25,509$3,750.45$37,536$5,121.41$12.0KABBV
8$34,347$7,052.64$50,079$8,338.38$15.7KABBV
9$50,987$14,235.48$69,753$14,065.80$18.8KABBV
10$86,234$31,678.26$102,337$24,771.77$16.1KABBV

CFRUY vs ABBV: Complete Analysis 2026

CFRUYStock

Compagnie Financière Richemont SA engages in the luxury goods business in Europe, the Middle East, Africa, Asia, and the Americas. The company operates through Jewellery Maisons, Specialist Watchmakers, and Online Distributors segments. It designs, manufactures, and distributes jewelry products; and precision timepieces, watches, and writing instruments, as well as clothing, and leather goods and accessories. The company offers its products under the Cartier, Van Cleef & Arpels, Buccellati, A. Lange & Söhne, Baume & Mercier, IWC Schaffhausen, Jaeger LeCoultre, Panerai, Piaget, Roger Dubuis, Vacheron Constantin, Watchfinder & Co., YOOX, NET-A-PORTER, MR PORTER, The Outnet, Alaïa, Chloé, Montblanc, Peter Millar, Purdey, Serapian, TIMEVALLEE, dunhill, Delvaux, and AZ Factory brands through own boutiques and online stores. Compagnie Financière Richemont SA was incorporated in 1979 and is headquartered in Bellevue, Switzerland.

Full CFRUY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CFRUY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CFRUY vs SCHDCFRUY vs JEPICFRUY vs OCFRUY vs KOCFRUY vs MAINCFRUY vs JNJCFRUY vs MRKCFRUY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.